Literature DB >> 27045101

Rociletinib: has the TIGER lost a few of its stripes?

K Dhingra1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27045101     DOI： 10.1093/annonc/mdw140

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

Review 1.  Covalent Inhibition in Drug Discovery.

Authors:  Avick Kumar Ghosh; Indranil Samanta; Anushree Mondal; Wenshe Ray Liu
Journal:  ChemMedChem       Date:  2019-03-26       Impact factor: 3.466

Review 2.  Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.

Authors:  Natalie M Andrews Wright; Glenwood D Goss
Journal:  Transl Lung Cancer Res       Date:  2019-11

Review 3.  New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?

Authors:  Nele Van Der Steen; Chiara Caparello; Christian Rolfo; Patrick Pauwels; Godefridus J Peters; Elisa Giovannetti
Journal:  Onco Targets Ther       Date:  2016-10-06       Impact factor: 4.147

4.  Assessment of Accuracy of Waterfall Plot Representations of Response Rates in Cancer Treatment Published in Medical Journals.

Authors:  Myung Sun Kim; Vinay Prasad
Journal:  JAMA Netw Open       Date:  2019-05-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.